Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Synthesis, in vitro anti-proliferative evaluation and molecular docking of new tetrazole-chalcone and tetrazole-pyrazoline hybrids.

Heidi S. Abd ElMonaem, Naglaa I. Abdel-Aziz, Mohammad A. Morsy, Farid A. Badria, Fardous ElSenduny, Mahmoud B. El-Ashmawy, Mohamed A. Moustafa.




Abstract

New hybrids of tetrazole moiety with different chalcone derivatives were synthesized. Reaction of these chalcones with hydrazine hydrate resulted in the formation of tetrazole-pyrazoline hybrids. Evaluation of the in vitro antiproliferative activity of all newly synthesized hybrids against three cancer cell lines and Vero-B normal cell line, using MTT-based assay, was performed. Most of the chalcone derivatives exerted superior activity against colon HCT-116 and prostate PC-3 cell lines, in comparison with cisplatin (IC50 = 20 and 5 µg/ml) and 5-FU (IC50 = 17.3 and 21.4 µg/ml), respectively. Compound 5a was found to be the most active antiproliferative agent against colon HCT-116 and prostate PC-3 cell lines (IC50 = 0.6 and 1.6 µg/ml) with high selectivity indices (SI = 6.66 and 2.50), respectively. Compound 8f, in particular, displayed wider spectrum of activity that included, in addition, excellent effect against breast MCF-7 cell lines with SI = 2.75. The available docking results revealed a good binding of 5b with HDAC2 and CYP17A1 that endorses the in vitro biological activity against the tested colon and prostate cell lines.

Key words: Tetrazole. Chalcone. Pyrazoline. Antiproliferative, Molecular docking.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.